TOUJEO®
DOSING IN PATIENTS WITH TYPE 2 DIABETES

**START** (new to basal)

- Recommended dose: 0.2 U/kg OD
- Diabetes Canada suggested dose: 10 units OD
- Based on the discretion of the healthcare provider.

**TRANSFER**

- Patients on OD basal insulin: 1:1 conversion
- Patients on BID basal insulin: Start TOUJEO® at 80% of previous total daily basal insulin dose

Monitor glucose frequently in the first weeks of therapy and titrate the dose of TOUJEO® per instructions and the dose of other glucose lowering therapies per standard of care to minimize the risk of hyperglycemia when transferring patients to TOUJEO®.[1]

**TITRATE your patients to target**

- Perform fasting SMBG ≥1 x/day and self-titrator to target
- FBG >7.0 mmol/L +1 unit
- TARGET FBG 4.0–7.0 mmol/L Keep the same dose

Dosage adjustments should be based on the individual’s metabolic needs, blood glucose monitoring results and glycemic control goal.[1]

Adapted from TOUJEO® SoloSTAR® Product Monograph, the Diabetes Canada Clinical Practice Guidelines Expert Committee, 2016 and Yale JF et al. Please refer to the Product Monograph for complete dosing and administration instructions.

**CONSIDERATIONS**

- Consider a lower starting dose, slower titration and higher targets for elderly or normal weight subjects’ Please refer to the Diabetes Canada Clinical Practice Guidelines for additional considerations.

The TOUJEO® SoloSTAR® Product Monograph outlines that the full glucose lowering effect of TOUJEO® may not be apparent for at least 5 days.[1]

TOUJEO® is indicated for once-daily subcutaneous administration in the treatment of adult patients (≥18 years) with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for glycemic control.[1]

OD=once daily; BID=twice daily; SMBG=self-monitoring blood glucose; FBG=fasting blood glucose.

* LANTUS® and TOUJEO® are not bioequivalent and are not directly interchangeable. A higher daily TOUJEO® dose may be needed to achieve target ranges for plasma glucose level when switching from LANTUS®.

† Clinical significance has not been established.
TOUJEO®
ONE-THIRD THE VOLUME OF LANTUS® FOR THE SAME NUMBER OF UNITS®

LANTUS®
100 U/mL

TOUJEO®
300 U/mL

Insulin glargine 100 U/mL (LANTUS®) and insulin glargine 300 U/mL (TOUJEO®) are not bioequivalent and are therefore not interchangeable without dose adjustment.

A higher daily TOUJEO® dose may be needed when switching from LANTUS® to achieve target ranges for plasma glucose level. Please refer to the TOUJEO® SoloSTAR® Product Monograph for more information on dosing.

Adapted from TOUJEO® SoloSTAR® Product Monograph.

Please consult the Product Monograph at http://products.sanofi.ca/en/toujeo-solostar.pdf for important information about:

- Contraindications in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container and during episodes of hypoglycemia
- Most serious warnings and precautions regarding hypoglycemia, administration, medication errors and LANTUS® and TOUJEO® not being interchangeable
- Other relevant warnings and precautions relating to combination of insulin, including TOUJEO®, with thiazolidinediones (TZDs); risk of hyperglycemia; considering the longer onset of action of TOUJEO® before stopping intravenous (IV) insulin treatment in patients with Type 1 diabetes; hypokalemia; sodium retention and edema; fluid retention and heart failure with concomitant use of peroxisome proliferator-activated receptor (PPAR)-gamma agonists TZDs; patients with renal impairment and hepatic impairment; risk of allergic reactions, injection site reactions, lipodystrophy and lipoatrophy, rash and antibody formation; risk of visual impairment; worsening of diabetic retinopathy and transient amaurosis; pregnant or nursing women; and geriatrics
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph may also be obtained by calling 1.888.852.6887.


Copyright © 2019 sanofi-aventis Canada Inc. All rights reserved.